Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Oncolytics Biotech Inc News

    1,14 $ +1,79% +0,02 $
    In : 1,0643 € | 01.05.24 21:30:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2JMW5
    ISIN: CA6823108759
    US-Symbol: ONCY
    Typ: Aktie

    Oncolytics Biotech Inc News

    30.04.24 - PR Newswire
    Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
    Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights PR Newswire
    25.04.24 - PR Newswire
    Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
    Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting PR Newswire
    25.04.24 - PR Newswire
    Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
    Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting PR Newswire
    11.04.24 - PR Newswire
    Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
    Oncolytics Biotech® Advances Toward Registration-​Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA PR Newswire
    11.04.24 - PR Newswire
    Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
    Oncolytics Biotech® Advances Toward Registration-​Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA PR Newswire SAN DIEGO ...
    02.04.24 - PR Newswire
    Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
    Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference PR Newswire
    07.03.24 - PR Newswire
    Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
    Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire
    05.03.24 - PR Newswire
    Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
    Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN PR Newswire
    04.03.24 - PR Newswire
    Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
    Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights PR Newswire
    28.02.24 - PR Newswire
    Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
    Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference PR Newswire
    14.02.24 - PR Newswire
    Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
    Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort PR Newswire
    14.02.24 - PR Newswire
    Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
    Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort PR Newswire
    09.01.24 - PR Newswire
    Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
    Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors PR Newswire
    09.01.24 - PR Newswire
    Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
    Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors PR Newswire
    04.01.24 - PR Newswire
    Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
    Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024 PR Newswire
    04.01.24 - PR Newswire
    Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
    Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024 PR Newswire
    07.12.23 - PR Newswire
    Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
    Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS PR Newswire
    07.12.23 - PR Newswire
    Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
    Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS PR Newswire
    09.11.23 - PR Newswire
    Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
    Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy PR Newswire
    09.11.23 - PR Newswire
    Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
    Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy PR Newswire

    Newssuche

    Videos

    newspaper
    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »